Molecular point-of-care testing for infectious diseases and antimicrobial resistance: integrated biosensing technologies, evidence maturity, and clinical and one health translation

Effective infectious-disease management requires diagnostic results early enough to inform isolation, referral, and antimicrobial treatment. Molecular point-of-care testing (POCT) addresses this need, but analytical sensitivity alone does not establish readiness for clinical use. This critical narrative review examines molecular POCT as an integrated sample-to-answer biosensing system. It connects CRISPR-Cas recognition, isothermal amplification, microfluidic sample handling, nanomaterial-assisted preparation and transduction, and smartphone readout with contamination control, matrix tolerance, multiplexing, calibration, and reagent stability. Respiratory infections, sexually transmitted infections, and antimicrobial-resistance (AMR) testing illustrate different clinical decision windows. We propose a five-domain framework distinguishing mechanistic feasibility, analytical characterization, clinical accuracy, usability and operations, and clinical utility and implementation. A structured comparison of representative primary studies applies the framework while separating authentic clinical specimens from contrived samples and reaction time from complete workflow time. The framework is an interpretive reporting aid, not a validated readiness score. Clinically evaluated cartridge systems provide stronger evidence of diagnostic accuracy and intended-user operation than many emerging prototypes; however, randomized evidence shows that rapid pathogen identification does not necessarily reduce antibiotic prescribing. Genotypic resistance detection is therefore distinguished from phenotypic susceptibility testing and from host-response or antimicrobial-residue measurements. A focused One Health section examines transferable engineering constraints in foodborne-pathogen detection, irrigation-water surveillance, and antimicrobial-exposure monitoring. Priorities for translation include internal process controls, transparent invalid-result reporting, prospective evaluation in intended-use settings, reproducible manufacturing, affordability, secure connectivity, and explicit links between a test result and an appropriate action.

Authors

Institutions

Publication Details

Journal
Frontiers in Bioengineering and Biotechnology
Published
2026-11-13
DOI
https://doi.org/10.3389/fbioe.2026.1993049
Primary Topic
Biosensors and Analytical Detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecular point-of-care testing for infectious diseases and antimicrobial resistance: integrated biosensing technologies, evidence maturity, and clinical and one health translation

Jie Wang, Zhe Chen, Xiaoxue Huang, Jing Yan et al.
4 links
Frontiers in Bioengineering and Biotechnology
Biosensors and Analytical Detection
article

Molecular point-of-care testing for infectious diseases and antimicrobial resistance: integrated biosensing technologies, evidence maturity, and clinical and one health translation

Jie Wang, Zhe Chen, Xiaoxue Huang, Jing Yan, Ruitao Yang
article en

Abstract

Effective infectious-disease management requires diagnostic results early enough to inform isolation, referral, and antimicrobial treatment. Molecular point-of-care testing (POCT) addresses this need, but analytical sensitivity alone does not establish readiness for clinical use. This critical narrative review examines molecular POCT as an integrated sample-to-answer biosensing system. It connects CRISPR-Cas recognition, isothermal amplification, microfluidic sample handling, nanomaterial-assisted preparation and transduction, and smartphone readout with contamination control, matrix tolerance, multiplexing, calibration, and reagent stability. Respiratory infections, sexually transmitted infections, and antimicrobial-resistance (AMR) testing illustrate different clinical decision windows. We propose a five-domain framework distinguishing mechanistic feasibility, analytical characterization, clinical accuracy, usability and operations, and clinical utility and implementation. A structured comparison of representative primary studies applies the framework while separating authentic clinical specimens from contrived samples and reaction time from complete workflow time. The framework is an interpretive reporting aid, not a validated readiness score. Clinically evaluated cartridge systems provide stronger evidence of diagnostic accuracy and intended-user operation than many emerging prototypes; however, randomized evidence shows that rapid pathogen identification does not necessarily reduce antibiotic prescribing. Genotypic resistance detection is therefore distinguished from phenotypic susceptibility testing and from host-response or antimicrobial-residue measurements. A focused One Health section examines transferable engineering constraints in foodborne-pathogen detection, irrigation-water surveillance, and antimicrobial-exposure monitoring. Priorities for translation include internal process controls, transparent invalid-result reporting, prospective evaluation in intended-use settings, reproducible manufacturing, affordability, secure connectivity, and explicit links between a test result and an appropriate action.

Frontiers in Bioengineering and BiotechnologyVol. 14
Jiangsu University (CN), University of Cambridge (GB)
Good health and well-being
Biosensors and Analytical Detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon